The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells
出版年份 2022 全文链接
标题
The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells
作者
关键词
-
出版物
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
Volume 1866, Issue 8, Pages 130152
出版商
Elsevier BV
发表日期
2022-04-15
DOI
10.1016/j.bbagen.2022.130152
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1
- (2022) Bekesho Geleta et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
- (2022) Dario P. Anobile et al. MOLECULES
- Breaking the cycle: Targeting of NDRG1 to inhibit bi‐directional oncogenic cross‐talk between pancreatic cancer and stroma
- (2021) Bekesho Geleta et al. FASEB JOURNAL
- The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer
- (2021) Syer C. Lim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models
- (2021) Mauro Niso et al. CELLULAR ONCOLOGY
- The growing evidence for targeting P-glycoprotein in lysosomes to overcome resistance
- (2020) Sven Marcel Stefan et al. Future Medicinal Chemistry
- Unique targeting of androgen‐dependent and ‐independent AR signaling in prostate cancer to overcome androgen resistance
- (2020) Syer C. Lim et al. FASEB JOURNAL
- Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux
- (2020) Julia H. Bormio Nunes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms
- (2020) Silvia Paukovcekova et al. Cancers
- Repurposing Cationic Amphiphilic Drugs and Derivatives to Engage Lysosomal Cell Death in Cancer Treatment
- (2020) Michelle Hu et al. Frontiers in Oncology
- The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6
- (2019) Sharleen V. Menezes et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms
- (2019) Antje Lindemann et al. CLINICAL CANCER RESEARCH
- Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.
- (2019) Kyung Chan Park et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ 2 ) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors
- (2018) Maria Laura Pati et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
- (2018) Kaviyarasi Renu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Platinum-based drugs: past, present and future
- (2016) Shahana Dilruba et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
- (2016) Guillemette E. Benoist et al. CLINICAL PHARMACOKINETICS
- COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway
- (2016) K.Y. Salim et al. EUROPEAN JOURNAL OF CANCER
- Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance
- (2016) Nicole Seebacher et al. FREE RADICAL BIOLOGY AND MEDICINE
- The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms
- (2016) Zhu-Ling Guo et al. Journal of Hematology & Oncology
- Zinc(II)–Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity
- (2016) Alexandra E. Stacy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure–Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance
- (2016) Alexandra E. Stacy et al. JOURNAL OF MEDICINAL CHEMISTRY
- A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC
- (2016) Nicole A Seebacher et al. Cell Death & Disease
- Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp)
- (2015) Patric J. Jansson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter
- (2015) Nicole A. Seebacher et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways
- (2015) Zaklina Kovacevic et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the “Triad of Death” in cancer by Di-2-pyridylketone thiosemicarbazones
- (2015) Patric J. Jansson et al. PHARMACOLOGICAL RESEARCH
- The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1
- (2015) Wensheng Liu et al. Oncotarget
- Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
- (2015) Vit Sestak et al. Oncotarget
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs
- (2014) Eliska Potuckova et al. PLoS One
- Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells
- (2013) K M Dixon et al. BRITISH JOURNAL OF CANCER
- P-glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration
- (2013) Tetsuo Yamagishi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The lysosome: from waste bag to potential therapeutic target
- (2013) Hanna Appelqvist et al. Journal of Molecular Cell Biology
- The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways
- (2012) Zaklina Kovacevic et al. ANTIOXIDANTS & REDOX SIGNALING
- Novel Chelators for Cancer Treatment: Where Are We Now?
- (2012) Angelica M. Merlot et al. ANTIOXIDANTS & REDOX SIGNALING
- N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis
- (2012) Wen Liu et al. EMBO Molecular Medicine
- The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)
- (2012) Zhiqiang Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo
- (2012) David B. Lovejoy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes
- (2011) D. B. Lovejoy et al. CANCER RESEARCH
- Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
- (2011) K. J. Gotink et al. CLINICAL CANCER RESEARCH
- Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration
- (2011) Seng Chuan Tang et al. INTERNATIONAL JOURNAL OF CANCER
- Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer
- (2010) A. M. Merlot et al. MOLECULAR PHARMACOLOGY
- Disposition of everolimus in mdr1a−/1b− mice and after a pre-treatment of lapatinib in Swiss mice
- (2009) C. Chu et al. BIOCHEMICAL PHARMACOLOGY
- Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors
- (2009) Yu Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells
- (2008) Egarit Noulsri et al. AMERICAN JOURNAL OF HEMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started